Two businesses share the product name on this page and almost nothing else: a row-crop track that sells traits and chemistry by the hectare and a protected-horticulture track that sells a licence by the gram, and the research ratios published for the entrants split at 10 to 19.4% of sales on one side against 18 to 30% on the other.
Trait Stacks Set The Entry Price On The Row-Crop Side. Bayer and Corteva compete on genetics that travel with a chemical package: Enlist and Intacta traits, DEKALB corn, Asgrow soybeans and Stoneville cotton, with more than 500 new hybrid varieties a year leaving Bayer's pipeline and Corteva's seed segment carrying US$9.9 billion of the US$17.4 to 17.8 billion it reported for 2025. Presence across several continents is compulsory in that track because a single customer may plant thousands of hectares, and a variety that fails in one latitude has to be replaced from a pipeline that was built somewhere else.
Horticulture Sells A Licence, And The Unit Is A Gram. Rijk Zwaan keeps more than 2,000 proprietary varieties across roughly 30 crops on EUR 684 million of net sales, which is about 10% of the world vegetable seed trade, and returns 30% of turnover, above EUR 204 million, to research. Enza Zaden works from US$450 to 500 million of sales at a similar reinvestment ratio near 30%, and Limagrain, the largest vegetable seed producer in the world, spends 16 to 18% of seed sales on breeding. The output of a hectare of protected tomatoes can be carried in a few hundred grams of hybrid seed, which is why the price is set per gram and per variety rather than per tonne.
The Margin Shows Up At The Gross Line Before Anywhere Else. Sakata carries JPY 92.92 billion of sales for 2024/25 at a gross margin above 45%, and KWS lifts its EBIT margin to 18% on EUR 1.68 to 1.82 billion of revenue while committing 19.4% of sales to research, the highest ratio in the row-crop group. Bayer owns the largest seed business here and also the least concentrated one, seed and traits at US$11.24 to 14.80 billion inside a crop science division of EUR 21.6 to 23.3 billion. A wide gross margin on a small book and a thin margin on a vast book are both viable, but they are not competing for the same capital.
Neither Track Can Be Scaled With Money Alone. The horticultural constraint is a germplasm library and a selection record measured in decades rather than a plant that can be duplicated: Enza Zaden has bred vegetables since 1938, Limagrain's Vilmorin line since 1743 and Rijk Zwaan since 1924, and each still runs its own trial stations. Scale in row crops buys distribution and registration coverage, which is repeatable, while scale in vegetables buys the right to keep testing, which is not. That asymmetry is why a company with under US$1 billion of sales can sit in the same table as a division reporting twenty times more.
Why The Score Band Is Narrower Than The Revenue Spread. The seed revenue behind this page spans roughly thirty times, from Enza Zaden's US$450 to 500 million to Bayer's US$11.24 to 14.80 billion, yet the scores run only from 78 to 89, because 25% of the index is category fit and 15% is infrastructure and both components reward a pure, well-equipped breeder over a large mixed one. A reader who wants to know which track is performing better should therefore look at reinvestment ratios and variety turnover rather than at the revenue column, which mixes two businesses that price their output on different units.
Seed is no longer only a vehicle for genetics: the treatment applied to it now carries disease suppression, drought tolerance and root development into the field, and the global market for that treatment reached US$10.02 billion in 2025.
Coating And Pelleting Are Factory Steps Rather Than Bought-In Services. Bayer runs more than 150 seed conditioning and coating plants and breeding stations; Sakata conditions seed in Japan, California, France, Brazil and China; DLF blends, cleans and coats grass seed in Denmark, New Zealand, Oregon, the Netherlands and Argentina. Owning that line is what lets a manufacturer ship a finished production unit instead of a measured quantity of germplasm, and it is the reason pelleting and coating capacity appears in the 15% infrastructure test on this page even though no breeder sells the coating itself as a product.
Microbes Have Become The Active Ingredient In The Bag. Bayer, Corteva and Syngenta made combined seed treatment technologies containing endophytes, nematode-attacking fungi such as Trichoderma atroviride and biostimulants a standard specification during 2025. The effect on the commercial life of a variety is direct: a hybrid that would otherwise age as competitors release new material keeps earning while the treatment around it is revised, so the breeder's revenue per variety extends without a new crossing being made.
Treatment Moves The Argument Away From Germination Rate. Once a lot leaves the plant carrying a fungicide, an insecticide and a biological, the grower compares a planted hectare rather than a laboratory score, and the specification of the package stays with the breeder. The comparison also moves to the treated unit price, which a breeder can defend with agronomic data in a way that a bare seed price cannot. This is one of the few places on this page where a small entrant can charge a premium without owning a trait patent, provided it can register the product in each destination market.
The Chemistry Owners And The Chemistry Buyers Are Not The Same Companies. Three of the ten sit inside organisations that already make crop protection chemistry, Bayer, Corteva and Syngenta, so treatment is an internal supply decision for them and a purchasing decision for the other seven. Limagrain, KWS, Longping, Rijk Zwaan, Sakata, DLF and Enza Zaden have to buy inputs, hold a coating specification of their own and justify the charge from trial results, which makes their treated-seed margin more exposed to the price of the active ingredients than the integrated entrants' margin is.
What To Ask Before Paying For A Treated Seed. The two questions that carry weight are whether the coating plant is owned or contracted and whether the biological component is registered in the market where the seed will be sown, because an unregistered additive cannot legally travel and a contracted plant imposes a delivery schedule the breeder does not control. Both answers are observable in an annual report: a company that owns coating capacity describes it, and a company that does not describes the technology instead. Treated seed is also the part of the propagation business least likely to be replaced by a cheaper unbranded substitute.
In vegetable seed a single resistance gene decides whether a variety may be planted at all, and the entrants that found one first have taken whole accounts in a single season.
Tomato Brown Rugose Fruit Virus Rewrote The Variety Lists. Enza Zaden was first to commercialise a tomato hybrid carrying high resistance (HR) to the virus, and the order surge that followed in Europe and North America lifted a breeder with US$450 to 500 million of sales into an account base it had spent decades trying to reach. The mechanism is unusually harsh for the breeder that arrives late: a grower who cannot plant a susceptible variety does not negotiate on price, and the seed for a protected tomato crop is replaced every season, so a lost account has to be won back with a new resistance rather than with a discount.
The Rest Of The Field Answers Within Two Seasons. Rijk Zwaan released more than 200 new disease-resistant varieties in 2025, a virus-resistant tomato among them, and works across cucumber, lettuce, pepper and melon, which matters because cucumber green mottle mosaic virus is the same kind of problem in cucumbers and a breeder holding resistant material in several protected crops can keep an account whole. Resistance is therefore a temporary advantage at best, and the entrants that hold one are those that can screen thousands of lines a year rather than those with the largest sales force.
Sugar Beet Shows What Locking A Standard Is Worth. KWS supplies around 70% of the world's sugar beet seed and released CR+ varieties carrying double resistance against virus yellows across Europe and North America while beet seed revenue rose 21%. A field crop planted on a rotation makes resistance more durable than in vegetables, because the selection pressure arrives less often, which is why a dominant share in beet can be defended for years while a tomato advantage lasts about as long as the next breeding cycle.
Row Crops Run The Same Race Through Traits And Quality. Corteva bought non-GMO resistant-starch durum wheat traits and the associated breeding material from Arcadia Biosciences to extend a pipeline that already leans on Enlist and Intacta traits, and Longping runs a gene-editing and biotechnology centre in Brazil as its route into tropical corn germplasm. Bayer's stacks in corn and soybeans, more than 500 new hybrids a year and a digital platform subscribed across 250 million acres show how the row-crop version of the race is run: on patent breadth, regulatory clearance and the number of markets a trait may enter.
What A Reader Should Check Before Trusting A Claim. A high-resistance rating and an intermediate one are not interchangeable in a planting plan, and resistance is written for named viruses rather than for disease in general, so the label rather than the marketing sentence carries the claim. The durable asset behind any resistance is the screening greenhouse, the quarantine facility and the breeding station, which is why the entrants with the largest trial networks keep replacing a gene before it fails. Watch the release cadence rather than the announcement: a breeder that publishes new resistant material every year is defending a share, and one that publishes a single breakthrough is buying time.
Four ownership structures appear on this page and each prices research differently: a co-operative answers to farmers, a family firm answers to nobody outside the family, a listed breeder answers to a share register, and a division answers to a group board.
The Co-Operative Puts Members Where Shareholders Would Sit. Limagrain has been owned by the farmers on the Limagne plain since 1965 and spends 16 to 18% of seed sales on breeding, and it took Vilmorin & Cie private in 2023 so that the co-operative could fund a breeding cycle longer than a quarterly reporting rhythm; in 2026 it secured a credit line of EUR 300 to 450 million from the European Investment Bank for climate-adaptive varieties. DLF is owned by the DLF AmbA co-operative and grows by buying breeding companies in both hemispheres, a route a listed rival could not take without diluting its share register.
Family And Employee Ownership Buys The Longest Horizon And The Thinnest Profit. Rijk Zwaan put 30% of turnover, above EUR 204 million, into research on EUR 684 million of net sales, and its net profit eased to EUR 68 million, down from EUR 80 million the year before, as the research bill and depreciation on the new Seed Connect Centre landed at once. Enza Zaden reinvests about 30% on US$450 to 500 million of sales and has been owned by the same family since 1938. No share register forces either company to protect the margin, and no outside capital is invited in, which is exactly how the highest reinvestment ratios in the group are financed.
The Listed Breeders Must Show A Margin Every Year. KWS committed 19.4% of sales to research and still lifted its EBIT margin to 18% and the dividend to EUR 1.00 per share; Sakata holds a gross margin above 45% on JPY 92.92 billion of sales for 2024/25 and answers to shareholders on the Tokyo Prime market under code 1377; Longping faces the Shenzhen market under 000998 with CITIC as controlling shareholder and a consolidated revenue band of RMB 8.565 to 16.039 billion that includes supply-chain turnover. A listed structure does not forbid long research, but it makes each year a referendum on the spending.
A Division Competes For Capital With The Rest Of Its Own Group. Bayer Crop Science and Syngenta Group both live inside larger organisations, and Bayer's reorganisation targets about EUR 2 billion of structural cost savings by the end of 2026, an exercise that reaches the crop science unit as overhead as much as it reaches the group. Syngenta is unlisted after withdrawing an application to list on Shanghai's STAR Market, so it has no share price to defend and no share register to read, and its numbers arrive through published results rather than through quarterly calls. For a reader, the structure is the first clue to how much of the reported profit is a choice.
What The Structure Decides In The End. Ownership sets who absorbs a failed variety: a co-operative spreads the loss across member deliveries, a family firm accepts a thinner year and keeps breeding, a listed company explains the miss to analysts, and a division argues for its capital against a chemical or pharmaceutical segment in the same accounts. The pattern on this page is worth noting, because the two entrants with the highest reinvestment ratios sit at the bottom of the ranking while the entrant with the widest sales base sits at the top, so the index is measuring commercial reach and category fit rather than research intensity.
Syngenta Group buys reach with capital and a service platform while Yuan Longping High-Tech buys germplasm and market access, and the two routes arrive at the same grower from opposite ends.
The Capital Route Starts With A Group That Can Fund Distribution. Syngenta Group reported US$28.4 billion of sales in 2025 with EBITDA of US$4.4 billion, up 13% while total sales slipped about 1%, and the seed book inside that figure is US$4.2 to 4.5 billion. The controlling shareholder, Sinochem Holdings, is a member of the 2025 Fortune Global 500 while the group itself is not, a distinction that matters less to a Chinese grower than the service platform does: the modern agriculture platform sells inputs and agronomy together, so the seed arrives as one line of a package that also contains crop protection and advice.
The Breeding Footprint Follows The Platform. Syngenta operates more than 100 seed production and processing bases and several high-technology breeding centres, including tomato breeding in the Netherlands, corn breeding in Illinois and sites in Beijing and Yangling, and reaches growers in over 100 countries with roughly 60,000 staff across the group. That combination, a chemical business, a seed business and a service layer sharing one customer file, is the opposite of the specialist strategy the Dutch entrants on this page follow, and it is why the group's seed share of turnover is smaller than its reputation suggests.
The Acquisition Route Buys A Position In Another Hemisphere. Longping reports a consolidated band of RMB 8.565 to 16.039 billion that includes supply-chain and input-distribution turnover, holds the leading domestic position in hybrid rice seed, and reached the top three in Brazilian genetically modified corn seed through the Morgan and Forseed businesses it controls. Its network is deliberately split: thirteen stations for rice, thirteen for corn and six for vegetables, backed by drying and processing plants of scale in Hunan, Gansu and Xinjiang, and operations in more than 20 countries from Brazil to the Philippines, with CITIC as controlling shareholder.
Germplasm Moves In Both Directions, Which Is The Point Of The Route. Longping's gene-editing and biotechnology centre in Brazil sends tropical and subtropical corn material north while Chinese material travels south, and Syngenta integrates European and Chinese research programmes in the same way. Germplasm that can be planted in both hemispheres doubles the number of breeding generations a year and shortens the interval between a cross and a commercial variety, and it also spreads the risk of a single season failing in one climate. That gain is the reason the round trip is worth the freight, the quarantine paperwork and the duplication of trial sites.
What Each Route Costs Its Owner. The capital route buys distribution and a service relationship but not disclosure: Syngenta is unlisted after withdrawing its Shanghai listing application, so its seed figures arrive once a year in a press release rather than every quarter in a filing. The acquisition route buys access and germplasm but adds currency exposure, overseas borrowing cost and integration work, and Longping's financial expenses have been pressed by both. Both routes share one operational constraint, in that every seed lot crossing a border depends on a phytosanitary certificate, so a market can close for reasons that have nothing to do with the quality of the variety inside the bag.
